Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.860
Neutral
RSI(14)
50.476
Neutral
STOCH(KDJ)(9,3,3)
13.396
Sell
ATR(14)
3.611
Low Volatility
CCI(14)
-136.337
Sell
Williams %R
96.327
Oversold
TRIX(12,20)
0.783
Sell
StochRSI(14)
0.000
Oversold
Kymera Therapeutics Inc
KYMR77.810USD
-0.310-0.40%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
5.58BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Kymera Therapeutics Inc
Currency: USD Updated: 2025-12-31Key Insights
Kymera Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 49/403 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 96.64.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kymera Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
23
analysts
Buy
Current Rating
96.636
Target Price
+2.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Kymera Therapeutics Inc Highlights
StrengthsRisks
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Growing
The company is in a growing phase, with the latest annual income totaling USD 47.07M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 47.07M.
Undervalued
The company’s latest PE is -21.56, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 80.49M shares, increasing 1.93% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 52.03K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-31The current financial score of Kymera Therapeutics Inc is 5.83, ranking 329/403 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.76M, representing a year-over-year decrease of 26.12%, while its net profit experienced a year-over-year decrease of 31.51%.
Score
Financials
6.50
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.82
Operational Efficiency
2.83
Growth Potential
5.91
Shareholder Returns
7.07
Kymera Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-31The current valuation score of Kymera Therapeutics Inc is 6.84, ranking 222/403 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.56, which is -82.23% below the recent high of -3.83 and -21.19% above the recent low of -26.12.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 49/403
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-31The current earnings forecast score of Kymera Therapeutics Inc is 8.87, ranking 44/403 in the Biotechnology & Medical Research industry. The average price target for Kymera Therapeutics Inc is 90.50, with a high of 138.00 and a low of 65.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
23
analysts
Buy
Current Rating
96.636
Target Price
+2.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Kymera Therapeutics Inc
KYMR
23
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-31The current price momentum score of Kymera Therapeutics Inc is 7.33, ranking 100/403 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 99.12 and the support level at 60.38, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
80.146
Sell
MA10
81.430
Sell
MA20
81.578
Sell
MA50
70.129
Buy
MA100
59.674
Buy
MA200
48.299
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-31The current institutional shareholding score of Kymera Therapeutics Inc is 10.00, ranking 1/403 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 111.88%, representing a quarter-over-quarter increase of 3.06%. The largest institutional shareholder is The Vanguard, holding a total of 5.41M shares, representing 6.78% of shares outstanding, with 15.44% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Baker Bros. Advisors LP
Avoro Capital Advisors LLC
Fidelity Management & Research Company LLC
BVF Partners L.P.
Wellington Management Company, LLP
Atlas Venture
BlackRock Institutional Trust Company, N.A.
Invus Public Equities Advisors, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-31The current risk assessment score of Kymera Therapeutics Inc is 6.26, ranking 33/403 in the Biotechnology & Medical Research industry. The company's beta value is 2.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.23
VaR
+6.60%
240-Day Maximum Drawdown
+52.55%
240-Day Volatility
+80.02%
Return
Best Daily Return
60 days
+41.55%
120 days
+41.55%
5 years
+45.51%
Worst Daily Return
60 days
-7.87%
120 days
-7.87%
5 years
-23.98%
Sharpe Ratio
60 days
+1.67
120 days
+1.83
5 years
+0.50
Risk Assessment
Maximum Drawdown
240 days
+52.55%
3 years
+68.59%
5 years
+83.54%
Return-to-Drawdown Ratio
240 days
+1.77
3 years
+0.69
5 years
+0.17
Skewness
240 days
+4.23
3 years
+2.65
5 years
+1.47
Volatility
Realised Volatility
240 days
+80.02%
5 years
+76.70%
Standardised True Range
240 days
+3.36%
5 years
+3.08%
Downside Risk-Adjusted Return
120 days
+515.85%
240 days
+515.85%
Maximum Daily Upside Volatility
60 days
+112.47%
Maximum Daily Downside Volatility
60 days
+75.18%
Liquidity
Average Turnover Rate
60 days
+1.12%
120 days
+1.22%
5 years
--
Turnover Deviation
20 days
-11.32%
60 days
+1.04%
120 days
+9.82%
Peer Comparison
Biotechnology & Medical Research
Kymera Therapeutics Inc
KYMR
7.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Kymera Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Kymera Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Kymera Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Kymera Therapeutics Inc?
To generate the financial health score of Kymera Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Kymera Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Kymera Therapeutics Inc.
How do we generate the company valuation score of Kymera Therapeutics Inc?
To generate the company valuation score of Kymera Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Kymera Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Kymera Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Kymera Therapeutics Inc.
How do we generate the earnings forecast score of Kymera Therapeutics Inc?
To calculate the earnings forecast score of Kymera Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Kymera Therapeutics Inc’s future.
How do we generate the price momentum score of Kymera Therapeutics Inc?
When generating the price momentum score for Kymera Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Kymera Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Kymera Therapeutics Inc.
How do we generate the institutional confidence score of Kymera Therapeutics Inc?
To generate the institutional confidence score of Kymera Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Kymera Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Kymera Therapeutics Inc.
How do we generate the risk management score of Kymera Therapeutics Inc?
To assess the risk management score of Kymera Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Kymera Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Kymera Therapeutics Inc.
